HCA
HCA Healthcare, Inc.
$423.11
+6.04 (+1.45%)
At close · Jul 7
Market Cap
$93.86B
Shares
221,839,800
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-15 | |
| 8-K | 2026-04-30 | 2026-04-27 | |
| 10-Q | 2026-04-29 | 2026-03-31 | |
| 8-K | 2026-04-28 | 2026-04-23 | |
| 8-K | 2026-04-27 | — | |
| 8-K | 2026-04-24 | — | |
| DEF 14A | 2026-03-13 | 2026-04-23 | |
| 8-K | 2026-02-25 | 2026-02-20 | |
| 10-K | 2026-02-10 | 2025-12-31 | |
| 8-K | 2026-01-27 | — | |
| 8-K | 2025-10-31 | 2025-10-27 | |
| 10-Q | 2025-10-30 | 2025-09-30 | |
| 8-K | 2025-10-27 | — | |
| 8-K | 2025-10-24 | — | |
| 10-Q | 2025-08-04 | 2025-06-30 | |
| 8-K | 2025-07-25 | — | |
| 8-K | 2025-07-11 | 2025-07-08 | |
| 8-K | 2025-06-10 | — | |
| 10-Q | 2025-05-01 | 2025-03-31 | |
| 8-K | 2025-04-29 | 2025-04-24 | |
| 8-K | 2025-04-25 | — | |
| DEF 14A | 2025-03-14 | 2025-04-24 | |
| 8-K | 2025-02-24 | 2025-02-18 | |
| 8-K | 2025-02-21 | 2025-02-18 | |
| 8-K | 2025-02-20 | — | |
| 8-K | 2025-02-18 | — | |
| 10-K | 2025-02-14 | 2024-12-31 | |
| 8-K | 2025-01-24 | — | |
| 10-Q | 2024-10-31 | 2024-09-30 | |
| 8-K | 2024-10-25 | — | |
| 8-K | 2024-08-12 | — | |
| 8-K | 2024-08-08 | 2024-08-07 | |
| 10-Q | 2024-07-29 | 2024-06-30 | |
| 8-K | 2024-07-23 | — | |
| 10-Q | 2024-05-02 | 2024-03-31 | |
| 8-K | 2024-04-30 | 2024-04-25 | |
| 8-K | 2024-04-26 | — | |
| DEF 14A | 2024-03-15 | 2024-04-25 | |
| 8-K/A | 2024-02-26 | 2024-01-24 | |
| 8-K | 2024-02-26 | 2024-02-22 | |
| 8-K | 2024-02-23 | — | |
| 8-K | 2024-02-21 | 2024-02-20 | |
| 10-K | 2024-02-16 | 2023-12-31 | |
| 8-K | 2024-01-30 | 2024-01-24 | |
| 8-K | 2023-11-09 | — | |
| 10-Q | 2023-10-26 | 2023-09-30 | |
| 8-K | 2023-10-24 | — | |
| 10-Q | 2023-08-02 | 2023-06-30 | |
| 8-K | 2023-07-27 | — | |
| 8-K | 2023-07-10 | — |
Showing 1–50 of 113 filings
Key facts
CIK
860730
CUSIP
40412C101
13F (30d)
78 filings
52 filers
Visit website
Investor relations